Estimated prevalence, incidence and healthcare costs of Sjögren’s syndrome in France: a national claims-based study

• DOI: 10.1136/rmdopen-2023-003591
• Publication Date: 2024-02-02T18:07:22Z
• Authors: Raphaele Seror; Laurent Chiche; Maxime Beydon; Guillaume Desjeux; Joe Zhuo; Virginie Vannier-...; Valérie Devauchel...
• Keywords: Hydroxychloroquine

Objectives To estimate prevalence, incidence and mortality rates, annual healthcare costs of primary Sjögren’s syndrome (pSS) SS associated with other autoimmune disorders (SS+AID) in France. Methods French national claims-based study within the prospective Système National des Données de Santé database that includes majority population. An algorithm was developed to identify patients SS-related claims were analysed between 2011 2018. Results Overall, 23 848 pSS 14 809 SS+AID identified. From 2018, prevalence rate increased slightly for (23–32 per 100000) (16–20 100 000), females comprising 90%–91% 92%–93% cases, respectively. The 000 persons decreased from 2012 (pSS: 4.3; SS+AID: 2.0) 2017 0.7; 0.3). Mortality rates 2018 (0.2–0.8) or (0.1–0.5); mean age death also increased. Artificial tears hydroxychloroquine most common drug reimbursements. Less than half received specialist care a dentist ophthalmologist. Healthcare exceeded expected chronic diseases. Conclusion In this large population study, low confirms it is an orphan disease. clinically economically burdensome; these findings may help clinicians better understand routine by patients.